Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Aug 18.
Published in final edited form as: Aliment Pharmacol Ther. 2013 May;37(9):916–917. doi: 10.1111/apt.12280

Commentary: Non-alcoholic fatty pancreas: Toward an uncharted territory - authors' reply

Niraj S Patel 1, Rohit Loomba 2,3
PMCID: PMC4135375  NIHMSID: NIHMS490682  PMID: 23551158

We appreciate the insightful comments by Kwok et al. on our manuscript entitled, “Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.”1 In their commentary, Kwok et al. discuss important caveats regarding the radiographic evaluation and quantification of pancreatic fat content. Although liver fat content estimation by proton-density-fat-fraction (PDFF) using magnetic resonance imaging (MRI) has been validated by comparison with MR spectroscopy-determined liver fat content and liver histology-determined steatosis grade,2, 3 we agree that estimation of pancreatic PDFF using MRI has not been validated using pancreatic histology, and further studies are needed to determine the threshold at which pancreatic fat accumulation leads to adverse outcomes. In addition, Kwok et al. point out that the inverse association between pancreatic fat and liver fibrosis may be related to patient selection and due to the use of insulin sensitizing agents amongst diabetic patients. Previous studies have shown that diabetes is associated with increased risk of nonalcoholic steatohepatitis (NASH) and advanced fibrosis.4 In the present study, although more patients with grade 1 steatosis had diabetes, the increased risk of fibrosis in diabetic patients and the inverse relationship between liver steatosis and fibrosis may also explain this finding. As Kwok et al. pointed out, pancreatic biopsy is not possible to document presence of pancreatic fibrosis, we were not able to provide information regarding pancreatic fibrosis. In future, advanced MRI techniques may become available to identify and quantify pancreatic fibrosis. These advanced imaging techniques may help in improving our understanding of the long-term consequences of fat deposition in the pancreas and whether pancreatic fat deposition leads to pancreatic fibrosis. We agree that additional longitudinal studies are needed to provide further insight in this area.

Acknowledgements

The authors' declarations of personal and financial interests are unchanged from those in the original article.1

References

  • 1.Patel NSPM, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 doi: 10.1111/apt.12237. (in press). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial. Hepatology. 2012;56:922–932. doi: 10.1002/hep.25731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22–29. doi: 10.1111/j.1365-2036.2012.05121.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–951. doi: 10.1002/hep.25772. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES